TAC1 and type 2 diabetes mellitus: The unfavorable effects of this drug-drug interaction and the roleof substance P are now subjects of an ongoing clinical trial in patients with T2DM(Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure; NCT02130687).